COVID-19 Vaccine Shows Immune Response In 90% Of Patients
A COVID-19 vaccine that has been developed in China appears to be safe and effective.
According to UPI, the vaccine successfully induced an immune response against the virus in a small trial.
95% of trial participants who received a high dose of the vaccine and 91% of those given a lower dose had immune responses.
The study participants developed the immune response within 28 days of receiving the vaccination.
The vaccine is based on a weakened human common cold virus, or adenovirus.
The virus can infect human cells but is incapable of causing disease.
According to UPI, the vaccine successfully induced an immune response against the virus in a small trial.
95% of trial participants who received a high dose of the vaccine and 91% of those given a lower dose had immune responses.
The study participants developed the immune response within 28 days of receiving the vaccination.
The vaccine is based on a weakened human common cold virus, or adenovirus.
The virus can infect human cells but is incapable of causing disease.